Cargando…

PB2298: THE RELATIONSHIP BETWEEN PLATELET SPECIFIC ANTIBODIES AND THE SEVERITY OF NEWLY DIAGNOSED PEDIATRIC ITP

Detalles Bibliográficos
Autor principal:	Dong, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431572/ http://dx.doi.org/10.1097/01.HS9.0000852020.73301.fd

Ejemplares similares

PB2297: THE PREDICTIVE VALUE OF PLATELET SPECIFIC ANTIBODIES FOR THE FIRST-LINE TREATMENT EFFECT IN NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

PB2298: CHRONIC HEPATITIS B VIRAL ACTIVITY IS AN INDEPENDENT PROGNOSTIC FACTOR OF LYMPHOMA
por: Lee, Ho Sup, et al.
Publicado: (2023)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

PB2615: HOW WILL COVID-19 RELATED SYMPTOMS AND PLATELET COUNTS CHANGE IN ITP PATIENTS AFTER COVID-19 INFECTION?
por: Chen, Xiaoli, et al.
Publicado: (2023)

PB2620: NIGHTTIME SYMPTOMS ARE ASSOCIATED WITH FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

PB2630: ASSESSEMENT OF THE MANAGEMENT OF ITP IN ADULTS IN AN INTERNAL MEDICINE DEPARTMENT IN ALGERIA
por: Imene, Semoud, et al.
Publicado: (2023)

PB2610: EPIDEMIOLOGY AND TREATMENT OF ITP: A SINGLE CENTRE, REAL-WORLD EXPERIENCE
por: Patel, Priya, et al.
Publicado: (2023)

PB2577: INFECTIONS AND THEIR RELATIONSHIP WITH EARLY MORTALITY IN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA
por: Ontiveros-Austria, Juan Luis, et al.
Publicado: (2023)

PB2632: DILLEMAS AND CHALLENGES IN ITP TREATMENT OF A PATIENT WITH THROMBOTIC AND HEMORRHAGIC EVENTS DEVELOPMENT
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

PB2605: EFFICACY AND SAFETY OF MRNA COVID VACCINES IN ITP PATIENTS: A MONOCENTRIC REAL-LIFE STUDY
por: D’angelo, Simona, et al.
Publicado: (2023)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
por: Siala, N., et al.
Publicado: (2022)

PB1796: DETERMINATION OF THE RELATIONSHIP BETWEEN NEXT GENERATION SEQUENCING AND FLOW CYTOMETRY RESULTS IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA
por: Yavasoglu, I., et al.
Publicado: (2022)

PB2358: SIGNIFICANT INCREASE IN NEWLY DIAGNOSED HEMATOLOGICAL MALIGNANCIES FOLLOWING LOCKDOWN EASE IN CROATIA
por: Simunic, M., et al.
Publicado: (2022)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB2009: OPPORTUNITIES OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Kliuchagina, I., et al.
Publicado: (2022)

PB2136: THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

PB1954: PROGNOSTIC ANALYSIS OF GENE MUTATIONS ON TIME-TO-FIRST TREATMEN IN 93 NEWLY DIAGNOSED CHRONIC LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Xiang, Xixi, et al.
Publicado: (2023)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB1877: EFFECTS OF VENETOCLAX-BASED COMBINATIONS FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN CLINICAL SETTINGS
por: Park, Young Seob, et al.
Publicado: (2023)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

PB2036: RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA
por: VA, A., et al.
Publicado: (2022)

PB2017: YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A TUNISIAN SINGLE-CENTER EXPERIENCE
por: Kallel, F., et al.
Publicado: (2022)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

PB2142: CLINICAL CHARACTERISTICS AND OUTCOMES OF NEWLY DIAGNOSED PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED LYMPHOMA ADMINISTERED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
por: Wang, C., et al.
Publicado: (2022)

PB2596: OPTIMIZING PLATELET TRANSFUSION FOR CLINICAL PRACTICE. DO PLATELETS AGE MATTER FOR THERAPEUTIC PLATELETS TRANSFUSION?
por: Attallah, Samy, et al.
Publicado: (2023)

PB2635: FEATURES OF PLATELET PATHOLOGY IN PREGNANT WOMEN
por: Zaynutdinova, Dilafruz, et al.
Publicado: (2023)

PB2639: CHANGES IN PLATELETS IN CHRONIC LIVER DISEASES
por: Nuriddinova, Nodira
Publicado: (2023)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL
por: Yohannan, B., et al.
Publicado: (2022)

PB2001: A LOOK INTO THE REAL WORLD: PICTURE OF NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE TREATED PATIENTS IN THE FRONTLINE SETTING. CARINAE STUDY
por: de Arriba de la Fuente, F., et al.
Publicado: (2022)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a5nsgdlndn3n080vqortll359j